Perioperative tumor cell dissemination in patients with primary or metastatic colorectal cancer by Tralhão, JG et al.
ARTICLE IN PRESS
Available online at www.sciencedirect.comEJSO xx (2009) 1e5 www.ejso.comPerioperative tumor cell dissemination in patients with primary
or metastatic colorectal cancer
J.G. Tralh~ao a,b,*, E. Hoti c, M. Seroˆdio a, P. Laranjeiro d, A. Paiva d, A.M. Abrantes b,
M.L. Pais d, M.F. Botelho b, F. Castro Sousa a
a Department of Surgery, Surgery 3, Faculty of Medicine, Coimbra University Hospital, Coimbra, Portugal
b Biophysics and Biomathematics Institute, IBILI, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
c Liver Transplant Unit, Saint Vincent’s University Hospital, Elm Park, Dublin 4, Ireland
d Center of Histocompatibility of Center, Coimbra, Portugal
Accepted 2 July 2009AbstractIntroduction: Although there is general correlation between the TNM stage of colorectal cancer (CRC) and its prognosis, there is often
significant variability of tumor behaviour and individual patient outcome, which is unaccounted for by pathologic factors alone. Our
aim was to estimate perioperative tumor cell dissemination in patients with primary or CRC liver metastases as a possible factor influencing
the outcome.
Methods: Forty patients were prospectively enrolled in the study from the year 2007 to 2008. Eighteen patients had histologically proven
CRC (50% rectal, 44% colonic, 6% colonic and rectal). Sixteen patients (47%) had CRC liver metastases only. The remaining six patients
who underwent colon or liver resection for benign conditions, acted as the control group. All patients with malignant pathologies had R0
resections. Blood samples were taken before the surgical incision (T0), immediately after tumor resection (T1) and at the end of the surgical
intervention (T2). Data acquisition was performed using a dual-laser FACSCalibur flow cytometer. Circulating malignant cells were iden-
tified as being CD45/cytokeratinþ.
Results: The analysis of patients overall (CRC resection subgroup and hepatectomy subgroup) revealed that there was no statistically sig-
nificant difference of the tumoral cell count in the blood per million of hematopoietic cells at T0, T1 and T2.
Conclusions: This study demonstrates no differences in the detected circulating numbers of tumor cells at different stages of surgical
intervention.
 2009 Elsevier Ltd. All rights reserved.
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Colorectal cancer (CRC) is a common and often life-
limiting disease. Approximately 20e45% of patients with
CRC undergoing curative resection subsequently develop
local recurrence or metastatic disease in lymph nodes, liver,
lung and peritoneum.1,2
Although there is general correlation between the TNM
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unaccounted for by pathologic factors alone. The detection
of lymph node (LN) metastases constitutes the most impor-
tant prognostic factor in CRC and as the primary indicator
of disease spread, LN status determines the choice of post-
operative adjuvant chemotherapy. However, the limitations
of TNM staging are emphasised by the considerable prog-
nostic heterogeneity of patients within a given tumor stage
(not all patients with LN-negative tumors are cured and not
all patients with LN-positive tumors die from their disease).
This resulted in a number of efforts to develop more accu-
rate staging protocols.3e6
Tumor progression after curative resection of CRC is
caused by tumor cell dissemination, currently undetectedsemination in patients with primary or metastatic colorectal cancer, Eur J
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disseminated tumor cells could help to identify a subgroup
of patients at risk for disease relapse that could benefit from
adjuvant therapy.6,7 In this context, flow cytometry is one of
the methods used to identify subgroups at risk for disease
relapse. Flow cytometry allows an accurate quantification
of cells and at the same time a multi-parameter character-
ization of each cell present in the blood samples. This tech-
nique is widely used in the detection of rare events, such as
minimal residual disease in hematological malignancies.
Disseminated CRC cells have immunophenotypic charac-
teristics distinct from those of hematopoietic cells, which
allow their identification and quantification in peripheral
blood by flow cytometry.
The aim of the study was to determine whether resection
of the primary tumor or CRC liver metastases would lead to
an increased dissemination of cancer cells.
Patients and methodsPatientsThis prospective study included 40 patients who had un-
dergone surgery in our institution from the year 2007 to
2008. There were 24 male patients with a median age
and 16 female patients with a mean age of 64 10 (range:
41e90).
Eighteen patients had histologically proven colorectal
cancer (50% rectal, 44% colonic, 6% colonic and rectal).
Sixteen patients had colorectal liver metastases only. The
remaining six patients, who acted as the control group
had benign conditions (sigmoid diverticulosis, hepatic ade-
noma and hemangioma).
All patients were preoperatively staged by biological
and radiological examinations. In addition, patients with
rectal cancer received mandatory magnetic resonance im-
aging (MRI). Similarly, MRI was performed also for pa-
tients with non-conclusive computed tomography imaging
(CT scan) concerning liver metastases originating from ei-
ther rectal or colonic primary tumors.
Seven patients diagnosed with locally advanced rectal
cancer (T3, T4, LN positive) received preoperative radio-
chemotherapy.
All patients operated for malignancy had R0 resections,
performed according to international standards with at least
10 cm resection margins for colonic tumors or a distal re-
section margin of at least 2 cm associated with pericolic,
perirectal and perivascular truncal lymphadenectomy for
rectal cancers. High vascular ligation and no touch tech-
nique were used for all resections. Similarly, in the group
of patients with liver metastases, liver resection was per-
formed with at least 1 cm surgical margin.
Liver interventions included: right hepatectomy (n¼ 4),
extended left hepatectomy (n¼ 1), left hepatectomy
(n¼ 1), central hepatectomy (n¼ 1), left lobectomy
(n¼ 4), bisegmentectomy (n¼ 3), segmentectomy (n¼ 2)Please cite this article in press as: Tralh~ao JG et al., Perioperative tumor cell dis
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had left lobectomy, two had associated right hemicolectomy.
The colorectal procedures included: total coloproctec-
tomy with ileostomy (n¼ 2), total colectomy (n¼ 2), sub-
total colectomy (n¼ 1), right hemicolectomy (n¼ 1), left
hemicolectomy (n¼ 3), anterior resection (n¼ 6), anterior
resection with ileostomy (n¼ 1) and lastly abdominal per-
ineal resection (n¼ 2).Blood sampling and processingBlood was sampled using central venous catheters be-
fore placing the surgical incision (T0), immediately after
tumor resection (T1) and at the end of the surgical interven-
tion (T2) and each time a volume of 12 ml was obtained. As
negative control, venous blood specimens were collected
from the six patients who underwent surgery for benign
conditions before (T0), during (T1) and after surgery (T2).
Peripheral blood samples were centrifuged at 540 g
for 10 min, the buffy coat was collected and placed in
a 50 ml tube. Fixative-free NH4Cl lysing solution was
added to each tube (10 ml of lysing solution per 1 ml of
buffy coat) and the samples were incubated for 45 min at
room temperature (RT) to lyse the remaining red blood
cells.
After the incubation period, the samples were centri-
fuged at 540 g for 10 min. The supernatant was discarded
and the cell pellet washed with 10 ml of phosphate-buffered
saline (PBS, Gibco, Paisley, Scotland, UK) (540 g for
10 min).
The cell pellet was stained with anti-CD45 (clone 30-
F11, BDB, San Jose, CA, USA) conjugated with peridinin
chlorophyll protein cyanine 5.5 (PerCP Cy5.5) and anti-
cytokeratin (clone MNF116, DakoCytomation, Glostrup,
Denmark) conjugated with fluorescein isothiocyanate and
incubated in the dark at RT for 30 min. At last, the samples
were washed twice in 10 ml of PBS and the cell pellet re-
suspended in 1 ml of PBS.
Data analysis was performed in a dual-laser FACSCali-
bur flow cytometer (BDB, San Jose, CA, USA) using the
CellQuest software (BDB, San Jose, CA, USA). First, a to-
tal of 20 000 events, corresponding to all nucleated cells in
the sample, was stored. To increase the sensitivity of the
technique, in a second step of acquisition, only cy-
tokeratinþ cells were acquired using an electronic live
gate.
Data analysis was performed using the Paint-a-Gate Pro
software (BDB, San Jose, CA, USA). Circulating CRC
cells were identified as being CD45/cytokeratinþ. The
monoclonal antibody anti-cytokeratin used recognized an
epitope present in keratin 5, 6, 8 and 17.Statistical analysisContinuous data were presented as mean and standard
deviation (SD). Skewed and non-gaussian continuous datasemination in patients with primary or metastatic colorectal cancer, Eur J
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U test or the KruskaleWallis test, whenever there were two,
three or more samples to compare); Chi-square test was ap-
plied for the purpose of comparing proportions. Statistical
analysis was performed using Statistica, version 7. A
p value of 0.05 was considered as statistically significant.EthicsWritten informed consent was obtained for all the en-
rolled patients. The protocol of the study conformed to
the ethical guidelines of the 1975 Declaration of Helsinki
and also with the guidelines of our institution.
ResultsPatients of the control groupIn this group of patients (n¼ 6), none of the studied tu-
mor markers were detected at any of the mentioned surgical
times (T0, T1 and T2).Patients with colorectal cancer or CRC liver
metastasesWe analyzed 102 blood samples from 34 patients with
malignancy and detected circulating cancer cells in 31
blood samples from 34 patients who underwent curative
surgical resection.
The median value of the tumoral cell count in the blood
per million of hematopoietic cells was 7 7 (range 0e26)
at T0 (before the placement of surgical incision). At T1
(immediately after the removal of the specimen) the tu-
moral cell count in the blood per million of hematopoietic
cells was 4 4 (range 0e13) and lastly at T2 (end of the
surgical intervention) the tumoral cell count in the blood
per million of hematopoietic cells was 4 6 (range
0e26). However, this value was statistically not significant
( p< 0.501).Patients with colorectal cancerIn this subgroup of patients the median value of the tu-
moral cell count in the blood per million of hematopoietic
cells was 6 8 (range 0e26) at T0. Instead, at T1 the tu-
moral cell count in the blood per million of hematopoietic
cells was 2 2 (range 0e6) and lastly at T2 the tumoral
cell count in the blood per million of hematopoietic cells
was 3 4 (range 0e10). Similar to the overall group of pa-
tients the value of tumoral cell count at T2 was statistically
non-significant ( p< 0.141).Patients with colorectal liver metastasesThe analysis in this subgroup of patients revealed that
the median value of the tumoral cell count in the bloodPlease cite this article in press as: Tralh~ao JG et al., Perioperative tumor cell dis
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0e14) at T0. Instead at T1 the tumoral cell count in the
blood per million of hematopoietic cells was 7 4 (range
0e13) and lastly at T2 the tumoral cell count in the blood
per million of hematopoietic cells was 6 9 (range 0e26),
which is statistically not significant ( p< 0.088).
Discussion
In this study we have investigated the hypothesis that cu-
rative resection of a primary or secondary colorectal tumor
can lead to shedding of malignant cells into the peripheral
circulation. Our results obtained by using flow cytometry
with the pancytokeratin antibody would suggest that such
procedures are not associated or do not disseminate tumoral
cells in the peripheral blood.Prognostic factors and management of colorectal
cancerTumor progression can result from disseminated tumor
cells in lymph nodes, blood or bone marrow, sites which
are not detected by current staging methods. The objective
of adjuvant therapy is to eradicate viable disseminated tu-
mor cells, thereby decreasing disease relapse and improv-
ing patients’ survival.8 Candidates for post-operative
adjuvant therapy are usually patients at high risk for disease
relapse, as judged by current clinical and pathological stag-
ing. In the group of patients without distant metastases,
lymph node metastases are the most important prognostic
factor.9 Consequently, adjuvant chemotherapy is recom-
mended for patients with positive lymph nodes. For patients
with colon cancer stage I or II, adjuvant chemotherapy can-
not achieve a survival benefit, and thus, adjuvant therapy is
not recommended for these patients. Although considered
at low risk, 10e20% of patients with colorectal cancer
stage I and II ultimately will develop recurrent disease.10,11
It is in this population that prognostic markers may identify
a subgroup of patients who are at a higher risk for disease
relapse and who may also benefit from adjuvant therapy, es-
pecially from antitumoral agents with low systemic toxicity
such as monoclonal antibodies, which have also proven to
be effective against dormant tumor cells.6,7 In this regard,
there are several studies that have demonstrated that tumor
cell detection is clearly related to an early relapse and de-
creased survival of the respective patients.6,7,12,13 This
new prognostic factor may change the surgical manage-
ment of patients with colorectal liver metastases and may
help to individualize the treatment of these patients with
systemic or regional chemotherapy.14Flow cytometry in the detection of disseminated
colorectal cancer cellsAmong the different approaches to screen disseminated
colorectal cancer cells in bone marrow aspirates, peripheralsemination in patients with primary or metastatic colorectal cancer, Eur J
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most widely used method. This method has the advantage
to allow cell morphology characterization, but presents
low sensitivity.6,15,16 RT-PCR based protocols have further
improved the sensitivity and specificity of detection sys-
tems for disseminated cancer cells, allowing the identifica-
tion of approximately one neoplastic cell in 107 normal
peripheral mononuclear blood cells.17
Several studies have proved that the sensitivity of flow
cytometry is similar to PCR’s, ranging from 104 to
105.16,18,19,20 A study based on serial dilutions of breast
cancer cells in normal peripheral blood, showed that, using
the appropriated markers, flow cytometry presented a sensi-
tivity ranging between 106 and 107.21 Despite this, flow
cytometry is not widely used in the detection of dissemi-
nated tumor cells in peripheral blood or bone marrow sam-
ples, probably because of the limited information in the
literature regarding the phenotype of these cells. Because
of the absence of tumor-specific target antigens, the dissem-
inating tumor cells are identified based on the expression of
epithelium-specific antigens such as cytoskeleton-associ-
ated cytokeratins, surface adhesion molecules, or growth
factor receptors, whose quantitative expression obtained
by flow cytometry is not well documented. Moreover, cyto-
keratin expression might vary along malignant transforma-
tions and different tumor stages.21,22 Other reasons that
have limited the use of flow cytometry in this field are
the absence of a consensus for the reagents and methods ap-
plied, the need for technical expertise and the long period
required for sample acquisition, in order to obtain a large
number of cells to achieve an acceptable sensitivity.
However, flow cytometry allows an accurate quantifica-
tion of cells and enables the immunophenotypic character-
ization of each cell in the sample. Besides the improvement
of flow cytometry technology, the development of new
high-speed flow cytometers allowing the acquisition of
20 000 events per second, has reduced dramatically the ac-
quisition period. Altogether these factors make flow cytom-
etry an attractive method for the quantification of rare
events. This technique has become a method of choice
for the detection of minimal residual disease in hematolog-
ical malignant neoplasms17,19,23,24 and, more recently, an
important tool in quantifying other rare events such as cir-
culating endothelial cells, circulating progenitor cells,19,25
mesenchymal stem cells25 and disseminated tumor cells
from CRC,26 small and non-small lung cancer,26 prostate
cancer27 and rhabdomyosarcoma.28
In this study, we used an anti-pancytokeratin monoclonal
antibody able to recognize an epitope present in cytokeratin
5, 6, 8 and 17; and anti-CD45 monoclonal antibody. The
analysis of the expression of both pancytokeratin and
CD45 together with the light scatter properties enabled us
to distinguish between non-hematopoietic cells (pan-
cytokeratinþ/CD45) and peripheral blood cells (pan-
cytokeratin/CD45þ). However, before we proceeded to
the quantification of disseminated CRC cells in peripheralPlease cite this article in press as: Tralh~ao JG et al., Perioperative tumor cell dis
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cells from tumor biopsies and verified the presence of two
distinct populations: the first with a low pancytokeratin ex-
pression and the second with a higher expression. Based on
previous proteomic studies in CCR showing a heightened
cytokeratin 8 expression in tumor tissue compared to nor-
mal mucosa from the same individual, we assume that
only those cells with higher pancytokeratin expression
were CRC cells.29,30 Therefore, when peripheral blood
samples were analyzed, we only considered as circulating
CRC cells those with characteristic light scatter properties,
CD45 and with high pancytokeratin expression.
In our results, none of the samples from patients with be-
nign conditions who had surgical resection demonstrated
the evaluated tumor markers. However, these tumor markers
are not limited only to the gastrointestinal epithelium, as
they have been found in a variety of cell types including ur-
othelial, Merkel cells and leucocytes in 1982.31 On the other
hand, several studies have also reported that in terms of mo-
lecular screening of circulating blood, the expression of sev-
eral tumor markers is limited to patients with colorectal
cancer with no expression seen in the controls.32,33ConclusionThis prospective study using flow cytometry (a very spe-
cific and sensitive technique) to detect circulating tumor
cells, demonstrated no differences in the circulating num-
bers of tumor cells detected at different times of the surgi-
cal intervention. These results would lead to the logical
questions: what is the impact of the ‘‘no touch’’ technique
in the oncological outcome of patients with primary colo-
rectal cancer or liver metastases? Do we need to use perio-
perative adjuvant therapy or to change the surgical
strategies to prevent intraoperative tumor cell shedding?
Our study does not suggest so; however, further studies
should be performed to answer the raised questions.
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